ISSN: 0093-7754

Journal Home

Journal Guideline

Seminars in Oncology Q1 Unclaimed

W.B. Saunders Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Seminars in Oncology is a journal indexed in SJR in Hematology and Oncology with an H index of 142. It has an SJR impact factor of 1,464 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,464.

Seminars in Oncology focuses its scope in these topics and keywords: cancer, breast, role, patients, promising, smoking, systems, therapies, treatment, bone, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Hematology (Q1) Oncology (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

1,464

SJR Impact factor

142

H Index

60

Total Docs (Last Year)

140

Total Docs (3 years)

3615

Total Refs

680

Total Cites (3 years)

129

Citable Docs (3 years)

3.71

Cites/Doc (2 years)

60.25

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

CA - A Cancer Journal for Clinicians Q1
Journal of Hematology and Oncology Q1
Blood Q1
The Lancet Haematology Q1
Blood Cancer Journal Q1

Compare this journals

Aims and Scope

Best articles by citations

How are bisphosphonates used today in breast cancer clinical practice?

Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussions

Angiogenesis-dependent diseases

The continuing problem of cardiac toxicity

Docetaxel (Taxotere) in combination with platinums in patients with non[ndash ]small cell lung cancer: Trial data and implications for clinical management

Temozolomide for recurrent high-grade glioma

Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non[ndash ]small cell lung cancer

Temozolomide for treating brain metastases

Docetaxel (Taxotere) in the treatment of non[ndash ]small cell lung cancer: An international update

Temozolomide in combination with other cytotoxic agents

Docetaxel (taxotere) plus trastuzumab (herceptin) in breast cancer

The role of nuclear factor-[kappa ]B in the biology and treatment of multiple myeloma

SHOW MORE ARTICLES

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non[ndash ]small cell lung cancer: A review of two phase III trials

Docetaxel and exisulind in hormone-refractory prostate cancer

Extending preclinical models of skeletal manifestations of malignancy to the clinical setting

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: Preliminary results

Cancer immunotherapy with natural killer cells

Dosing regimens and main adverse events of bisphosphonates

Pharmacokinetic profiles of doxorubicin in combination with taxanes

Docetaxel in the treatment of prostate cancer: Opportunities for combination regimens and challenges to development

Cancer in older persons: an international issue in an aging world

Bisphosphonates in oncology: Breast cancer and beyond

Bisphosphonates in the prevention of bone metastases: Current evidence

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer